Cala Health has unveiled new clinical results supporting its TAPS therapy for treating essential tremor (ET), showcased at the American Academy of Neurology (AAN) meeting. The Cala kIQ device, a non-invasive, FDA-cleared wearable, delivers personalized neurostimulation via the wrist to reduce hand tremors in ET and Parkinson’s patients.
Key Findings:
- Improved Tremor Severity: In the PROSPECT study of 263 participants, over 80% reported improved tremor control in daily activities after 1–3 months of regular TAPS use.
- Brain Network Impact: Research showed that TAPS modulates neural activity in the VIM nucleus of the thalamus—the same brain region targeted by deep brain stimulation (DBS). Improvement was seen in both treated and untreated limbs.
- Cost Reduction: A 12-month study comparing 153 TAPS users with a 306-patient control group demonstrated reduced ET-related healthcare costs and improved patient functioning.
Cala was also named to Fast Company’s 2025 Most Innovative Medical Device Companies list, marking its leadership in wearable neuromodulation for tremor relief.
Follow MEDWIRE.AI for the latest in neurotech and wearable innovation.
